Literature DB >> 6188916

Central hemodynamics of beta-adrenoceptor blocking drugs: beta 1 selectivity versus intrinsic sympathomimetic activity.

T L Svendsen.   

Abstract

It was the purpose of the present study to assess the hemodynamic effects of adrenergic beta-receptor blocking drugs possessing intrinsic sympathomimetic activity (ISA) and/or beta 1 selectivity, both at rest and during exercise. The hemodynamic effects of seven different beta-blockers (propranolol, atenolol, acebutolol, ICI 72,222, ICI 89,406, and pindolol) were studied at rest in patients with ischemic heart disease. Heart rate (HR), cardiac output (CO), arterial blood pressure (BP), and pulmonary artery pressure (PP) were determined. At rest, it was possible to subdivide the various beta-blockers into three main groups according to the degree of ISA. One group without ISA, including propranolol and atenolol, reduced CO by 25% and HR by 15%. A second group with moderate ISA, represented by practolol, acebutolol and ICI 72,222, reduced CO only by 15% and HR by 10%. A third group with pronounced ISA, represented by pindolol and ICI 89,406, did not change CO and HR significantly. All three groups consisted of drugs both with and without beta 1 selectivity. During exercise, pindolol and propranolol reduced CO, HR, and BP to the same extent. In conclusion, the central hemodynamic response to beta-blockers at rest is determined by the degree of ISA, whereas beta 1 selectivity does not modify the central hemodynamic response to beta-blockade. However, the hemodynamic differences between adrenergic beta-blocking drugs with and without ISA disappear in situations with increased sympathetic drive, such as exercise.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188916

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Vasodilatation in hypertension: the relevance of ISA. Concluding paper.

Authors:  A Zanchetti
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

Review 2.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

3.  Dynamics of beta-adrenoceptor blockade with cetamolol.

Authors:  J Coelho; K Schnelle; L Joubert; D Ventura; J Mullane
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 4.  Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.

Authors:  J G Riddell; R G Shanks; R N Brogden
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

5.  Increased Renal Dysfunction, Apoptosis, and Fibrogenesis Through Sympathetic Hyperactivity After Focal Cerebral Infarction.

Authors:  Yingyuan Cai; Xiaowei Lu; Xi Cheng; Qiushi Lv; Gelin Xu; Xinfeng Liu
Journal:  Transl Stroke Res       Date:  2021-03-12       Impact factor: 6.800

Review 6.  Post-valvular surgery multi-vessel coronary artery spasm - A literature review.

Authors:  Francesco Formica; Oluwaseun Adebayo Bamodu; Serena Mariani; Giovanni Paolini
Journal:  Int J Cardiol Heart Vasc       Date:  2015-10-30

Review 7.  Coronary Vasospastic Angina: A Review of the Pathogenesis, Diagnosis, and Management.

Authors:  Rajan Rehan; James Weaver; Andy Yong
Journal:  Life (Basel)       Date:  2022-07-27

Review 8.  Coronary artery spasm: review and update.

Authors:  Ming-Jui Hung; Patrick Hu; Ming-Yow Hung
Journal:  Int J Med Sci       Date:  2014-08-28       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.